Vitroscope, a biotech company based in Trondheim, has successfully raised $7 million to advance its technology for studying living human tissue. This financing package consists of a $5 million seed round led by Cerberus Ventures and YZR Capital, alongside $2 million received from the Research Council of Norway.
Specializing in automated perfusion platforms, Vitroscope offers solutions that maintain living tissue under controlled conditions, thereby enabling researchers to explore immune activity and disease mechanisms over time. The newly acquired funds will be directed towards the commercial rollout of its vitro.alive benchtop platform and the validation of a higher-throughput system called vitro.scale.
With this funding, Vitroscope aims to enhance lab capabilities for drug discovery and translational research, ultimately addressing limitations evident in traditional cell culture methods.
